{"id":10709,"date":"2020-09-10T17:29:29","date_gmt":"2020-09-10T11:59:29","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=10709"},"modified":"2021-07-24T12:58:05","modified_gmt":"2021-07-24T07:28:05","slug":"recent-pharma-happenings-for-pfizer-oncoimmune-recursion","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-pfizer-oncoimmune-recursion","title":{"rendered":"Pfizer-BioNTech COVID-19 vaccine trials; OncoImmune raises $56 M; Recursion Pharma nets $239 M; Breast cancer research updates"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69f452ad964a0\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69f452ad964a0\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-pfizer-oncoimmune-recursion\/#Pfizer_BioNTech_report_shows_the_immune_response_in_animals_to_COVID-19\" >Pfizer, BioNTech report shows the immune response in animals to COVID-19&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-pfizer-oncoimmune-recursion\/#Inhibiting_tumor_cell_division_to_avert_breast_cancer\" >Inhibiting tumor cell division to avert breast cancer<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-pfizer-oncoimmune-recursion\/#OncoImmune_captures_USD_56_Million_for_COVID-19_tests_and_leukemia_treatment\" >OncoImmune captures USD 56 Million for COVID-19 tests and leukemia treatment<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-pfizer-oncoimmune-recursion\/#Recursion_Pharma_nets_USD_239_Million_and_an_AI_research_contract_with_Bayer\" >Recursion Pharma nets USD 239 Million and an AI research contract with Bayer<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Pfizer_BioNTech_report_shows_the_immune_response_in_animals_to_COVID-19\"><\/span><strong>Pfizer, BioNTech report shows the immune response in animals to COVID-19&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Pfizer and its partner BioNTech have five potential <strong><a href=\"https:\/\/www.delveinsight.com\/blog\/coronavirus\/\">COVID-19<\/a><\/strong> vaccines in clinical trials, each based on a different mRNA format. The companies are now exhibiting that the most advanced candidate, BNT162b2, performed well in trials in which mice and macaques were infected with the coronavirus after inoculation.<\/p>\n\n\n\n<p>The companies informed that the vaccine candidate produced neutralizing antibodies against SARS-CoV-2, the virus that causes <strong><a href=\"https:\/\/www.delveinsight.com\/blog\/coronavirus-2019-ncov-is-now-covid-19\/\">COVID-19<\/a><\/strong>, macaques, and antigen-specific CD4+ and CD8+ T cells in both the nonhuman primates and mice. Those T cell responses indicate an anti-viral immune attack according to the companies.<\/p>\n\n\n\n<p>Pfizer and BioNTech reported that after one shot and a booster shot, the macaques that had been challenged with the COVID-19 virus had no viral RNA in their lower respiratory tracts when compared to non-immunized animals, most of which did show sign of the viral RNA.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Inhibiting_tumor_cell_division_to_avert_breast_cancer\"><\/span><strong>Inhibiting tumor cell division to avert breast cancer<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The cells become cancerous when they divide out of control. The scientists at Johns Hopkins University School of Medicine and the University of Oxford have found a potential way to block a type of human <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/er-her2-ve-breast-cancer-market\">breast cancer<\/a><\/strong> cell from multiplying by aiming a key mechanism, which depends on for division.<\/p>\n\n\n\n<p>The breast cancer cells the team targeted on overexpressed the TRIM37 protein. Treating them with a PLK4 inhibitor called centrinone interrupted the activity of a cell structure known as centriole, which these tumors rely on, but normal cells can bypass cell division, according to the results published in Nature journal.<\/p>\n\n\n\n<p>The findings could reveal the possibility of inhibiting PLK4 or other centriole function regulators from targeting this subset of breast cancer specifically. During their research, the scientists focused on <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/er-her2-ve-breast-cancer-market\">breast cancer<\/a><\/strong> cells, which have increased copy numbers of the 17q23 chromosomal region, an aberration found in about 9% of all primary breast tumors. These cells&#8217; division is highly reliant on centrioles that organize thin tubes of proteins, which give cells their shape and help separate DNA during division.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"OncoImmune_captures_USD_56_Million_for_COVID-19_tests_and_leukemia_treatment\"><\/span><strong>OncoImmune captures USD 56 Million for COVID-19 tests and leukemia treatment<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>OncoImmune has raised USD 56 million in a Series B as it looks to push on with late-stage tests for its experimental drug CD24Fc in both <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/acute-lymphoblastic-leukemia-all-market\">leukemia <\/a><\/strong>patients and its recent pivot to COVID-19.<\/p>\n\n\n\n<p>The drug is designed to regulate host inflammatory response to tissue injuries and has predominately been tested in graft-versus-host disease (GvHD).<\/p>\n\n\n\n<p>This can be a deadly result in <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/adult-t-cell-leukemia-lymphoma-market\">leukemia <\/a><\/strong>patients who have undergone hematopoietic stem cell transplantation. This is a bone marrow transplant, with cells coming from their own body or a donor, an allogeneic transplant.<\/p>\n\n\n\n<p>However, the body can sometimes be rejected in a condition that might happen after an allogeneic transplant. In graft-versus-host disease, the donated bone marrow or peripheral blood stem cells see the recipient&#8217;s body as foreign, and the donated cells\/bone marrow attack the body.<\/p>\n\n\n\n<p>In a recent midstage test, OncoImmune&#8217;s therapy displayed it could help patients gain GvHD survival, and, with its new cash haul, it will now continue into later-stage testing.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Recursion_Pharma_nets_USD_239_Million_and_an_AI_research_contract_with_Bayer\"><\/span><strong>Recursion Pharma nets USD 239 Million and an AI research contract with Bayer<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Recursion Pharmaceuticals has secured USD 239 million in new venture capital financing and a long-term partnership deal with Bayer to enhance its pipeline in fibrotic diseases of the <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/progressive-fibrosing-interstitial-lung-disease-pfild-market\">lung<\/a><\/strong>, <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/acute-renal-failure-arf-acute-kidney-injury-market\">kidney<\/a><\/strong>, heart, and others.<\/p>\n\n\n\n<p>The German drug-maker took the lead role in the artificial intelligence company&#8217;s series D round, conferring USD 50 million through its equity investment arm Leaps by Bayer.<\/p>\n\n\n\n<p>The investment round also garnered new backers in Casdin Capital, Catalio Capital Management, Laurion Capital Management, Samsara BioCapital, and others with additional support from Recursion&#8217;s returning investors Baillie Gifford, Mubadala, DCVC, Lux Capital, Obvious Ventures, Felicis Ventures, EPIC Ventures, Two Sigma Ventures, Advantage Capital and Intermountain Ventures.&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Pfizer, BioNTech report shows the immune response in animals to COVID-19&nbsp; Pfizer and its partner BioNTech have five potential COVID-19 vaccines in clinical trials, each based on a different mRNA format. The companies are now exhibiting that the most advanced candidate, BNT162b2, performed well in trials in which mice and macaques were infected with the [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":10712,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[1287,1262,460,639],"industry":[17225],"therapeutic_areas":[17231,17228],"class_list":["post-10709","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-biontech","tag-latest-news","tag-pfizer","tag-pharma-news","industry-pharmaceutical","therapeutic_areas-infectious-diseases","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Covid-19 vaccine trials | OncoImmune bags $56M | Recursion nets $239M<\/title>\n<meta name=\"description\" content=\"The vaccine candidate of Pfizer and BioNTech has produced neutralizing antibodies against COVID-19 in clincial trials...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-pfizer-oncoimmune-recursion\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Covid-19 vaccine trials | OncoImmune bags $56M | Recursion nets $239M\" \/>\n<meta property=\"og:description\" content=\"The vaccine candidate of Pfizer and BioNTech has produced neutralizing antibodies against COVID-19 in clincial trials...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-pfizer-oncoimmune-recursion\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-09-10T11:59:29+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:28:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/09\/10172341\/recent-pharma-happenings-for-pfizer-biontech-oncoimmune-recursion.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Covid-19 vaccine trials | OncoImmune bags $56M | Recursion nets $239M","description":"The vaccine candidate of Pfizer and BioNTech has produced neutralizing antibodies against COVID-19 in clincial trials...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-pfizer-oncoimmune-recursion","og_locale":"en_US","og_type":"article","og_title":"Covid-19 vaccine trials | OncoImmune bags $56M | Recursion nets $239M","og_description":"The vaccine candidate of Pfizer and BioNTech has produced neutralizing antibodies against COVID-19 in clincial trials...","og_url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-pfizer-oncoimmune-recursion","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2020-09-10T11:59:29+00:00","article_modified_time":"2021-07-24T07:28:05+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/09\/10172341\/recent-pharma-happenings-for-pfizer-biontech-oncoimmune-recursion.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-pfizer-oncoimmune-recursion","url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-pfizer-oncoimmune-recursion","name":"Covid-19 vaccine trials | OncoImmune bags $56M | Recursion nets $239M","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-pfizer-oncoimmune-recursion#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-pfizer-oncoimmune-recursion#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/09\/10172341\/recent-pharma-happenings-for-pfizer-biontech-oncoimmune-recursion.jpg","datePublished":"2020-09-10T11:59:29+00:00","dateModified":"2021-07-24T07:28:05+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"The vaccine candidate of Pfizer and BioNTech has produced neutralizing antibodies against COVID-19 in clincial trials...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-pfizer-oncoimmune-recursion"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-pfizer-oncoimmune-recursion#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/09\/10172341\/recent-pharma-happenings-for-pfizer-biontech-oncoimmune-recursion.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/09\/10172341\/recent-pharma-happenings-for-pfizer-biontech-oncoimmune-recursion.jpg","width":772,"height":482,"caption":"recent-pharma-happenings-for-pfizer-biontech-oncoimmune-recursion"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/09\/10172341\/recent-pharma-happenings-for-pfizer-biontech-oncoimmune-recursion-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">BioNTech<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">latest news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pfizer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">BioNTech<\/span>","<span class=\"advgb-post-tax-term\">latest news<\/span>","<span class=\"advgb-post-tax-term\">Pfizer<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 6 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Sep 10, 2020","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Sep 10, 2020 5:29 pm","modified":"Updated on Jul 24, 2021 12:58 pm"},"featured_img_caption":"recent-pharma-happenings-for-pfizer-biontech-oncoimmune-recursion","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/10709","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=10709"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/10709\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/10712"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=10709"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=10709"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=10709"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=10709"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=10709"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}